US antivirals giant Gilead Sciences recently announced that the US Food and Drug Administration (FDA) has accepted its New ...

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...

Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...

Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...

A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...

A WIRED investigation goes inside the Telegram groups targeting women who joined “Are We Dating the Same Guy?” groups on ...

Lenacapavir is already approved under the name Sunlenca as an HIV treatment for patients resistant to other medication ...

The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV ...

A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...

The study, published Jan. 30 in the Journal of Antimicrobial Chemotherapy, adds to growing evidence that lenacapavir may be a powerful new tool in the global anti-HIV drug arsenal.Approximately, 1 ...

A multi-national, multi-institutional study investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.

Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving ...